GlassScriptPhysician profile
Kevin M Lee
NPI 1669407706
$5,953.41
in general payments reported to CMS, 2019-2025
35 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $339 · 2021: $438 · 2022: $642 · 2023: $1,278 · 2024: $1,536 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,805 · Education: $77.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,804.93 |
| Education | $77.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $788.66 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $713.84 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $706.62 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Aurinia Pharma U.S., INC. | $377.78 | 2021-2024 | Lupkynis |
| Calliditas Therapeutics US INC. | $352.62 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $306.39 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $281.95 | 2020-2024 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $255.12 | 2021-2025 | |
| Vifor Pharma, INC. | $246.67 | 2019-2025 | Veltassa |
| Akebia Therapeutics INC | $244.34 | 2019-2024 | Auryxia, Vafseo |
| Glaxosmithkline, LLC. | $183.61 | 2021-2024 | Benlysta, Jesduvroq |
| Alexion Pharmaceuticals, INC. | $179.16 | 2021-2025 | Ultomiris |
| Ardelyx, INC. | $165.28 | 2024-2025 | Ibsrela |
| Horizon Therapeutics Plc | $158.86 | 2019-2023 | Krystexxa |
| Travere Therapeutics, INC. | $131.04 | 2023-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $112.37 | 2019 | |
| Zimmer Biomet Holdings, INC. | $107.04 | 2024 | Advantagerib |
| Novartis Pharmaceuticals Corporation | $100.70 | 2024-2025 | |
| Baxter Healthcare | $77.28 | 2022 | |
| Novo Nordisk INC | $58.99 | 2024-2025 | Wegovy, Rivfloza |
| Genentech, INC. | $53.45 | 2025 | |
| Daiichi Sankyo INC. | $53.24 | 2019-2020 | |
| Genzyme Corporation | $39.83 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.20 | 2024-2025 | Jardiance |
| Apellis Pharmaceuticals, INC. | $37.79 | 2025 | Empaveli |
| Scpharmaceuticals INC. | $24.09 | 2025 | |
| Ani Pharmaceuticals, INC. | $22.50 | 2024 | Purified Cortrophin Gel |
| Teleflex LLC | $21.84 | 2024 | Quikclot |
| Kyowa Kirin, INC. | $21.34 | 2023 | Crysvita |
| Cardiovascular Systems INC. | $18.23 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.85 | 2020 | |
| Biomerieux INC | $15.36 | 2019 | |
| Mallinckrodt Enterprises LLC | $14.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.59 | 2019 | |
| Alkermes, INC. | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.